0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters |

Genomic Sequencing in Newborn Screening Programs—Reply

Aaron J. Goldenberg, PhD, MPH; Richard R. Sharp, PhD
JAMA. 2012;307(20):1911-1912. doi:10.1001/jama.2012.3643.
Text Size: A A A
Published online

Extract

In Reply: Drs Dondorp and Greeley and their colleagues highlight the range of important ethical and societal issues that must be examined if genomic screening is to become a reality.

Although we agree with these commentators that the disclosure of genomic sequence data should be limited to clinically actionable information, medical applications of next-generation sequencing have been limited to date. As a result, deciphering the clinical meaning of genomic sequence data has proven difficult.1 In response, both the National Institutes of Health and the American College of Medical Genetics are leading efforts to clarify which genomic variants should be considered clinically actionable. These critical steps toward genomic screening will likely give rise to some initial criteria for determining clinical actionability. In the absence of consensus about clinical actionability, however, state NBS programs that pursue genomic screening have little guidance to draw upon in deciding which results to report. This may result in inconsistent approaches across states and declining confidence in the integrity of NBS.

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Letters

May 23, 2012
Wybo J. Dondorp, PhD; Guido M. W. R. de Wert, PhD; Martinus F. Niermeijer, MD, PhD
JAMA. 2012;307(20):2146. doi:10.1001/jama.2012.3621.
May 23, 2012
Siri Atma W. Greeley, MD, PhD; Michael E. Msall, MD; Kruti Acharya, MD
JAMA. 2012;307(20):1911-1912. doi:10.1001/jama.2012.3635.
CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();